Case Report: response of HER2-positive ductal carcinoma in situ to osimertinib with supporting in vitro evidence.

Baba S, Koketsu M, Kuroda H, Suzuki M, Nishihara H, Kato Y, Kawami H, Harada O

Open source

DOI
10.3389/fonc.2026.1845658
Published
2026
Container
Frontiers in oncology
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2026.1845658,
  title = {Case Report: response of HER2-positive ductal carcinoma in situ to osimertinib with supporting in vitro evidence.},
  author = {Baba S and Koketsu M and Kuroda H and Suzuki M and Nishihara H and Kato Y and Kawami H and Harada O},
  year = {2026},
  journal = {Frontiers in oncology},
  doi = {10.3389/fonc.2026.1845658},
  url = {https://doi.org/10.3389/fonc.2026.1845658}
}

RIS

TY  - JOUR
TI  - Case Report: response of HER2-positive ductal carcinoma in situ to osimertinib with supporting in vitro evidence.
AU  - Baba S
AU  - Koketsu M
AU  - Kuroda H
AU  - Suzuki M
AU  - Nishihara H
AU  - Kato Y
AU  - Kawami H
AU  - Harada O
PY  - 2026
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2026.1845658
UR  - https://doi.org/10.3389/fonc.2026.1845658
ER  - 

APA

S, B., M, K., H, K., M, S., H, N., Y, K., H, K., & O, H. (2026). Case Report: response of HER2-positive ductal carcinoma in situ to osimertinib with supporting in vitro evidence.. Frontiers in oncology. https://doi.org/10.3389/fonc.2026.1845658

Source records